DAC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
To begin industrial action for an "employee claim" it must be against a single-business enterprise, rather than multiple employers, it cannot even be part of so-called "pattern bargaining" seeking the same agreements across different enterprises, and it must not be taken before an enterprise agreement has expired. The union must get permission from the FWC to do a protected action ballot, and the FWC must grant an order where the union has a majority support determination and is "genuinely trying to reach an agreement" by negotiation. The ballot must state what kinds of action are proposed, and be overseen by the Australian Electoral Commission or an independent agent, and over 50% must turn out to vote, with over 50% being in favour of action. A union then must then give notice of three days to the employer, and start action within 30 days, or get an extension for another 30 days from the FWC, though action may continue indefinitely until there is agreement or the bargaining period is terminated. Protected industrial action is immune from liability in tort, so long as there is no personal injury, property damage or defamation. However, if industrial action is taken that is unprotected, the FWC must issue a "stop order", which may be backed by an injunction of the Federal Court, and ultimately sanctions for contempt of court including prison. There is a four-hour pay penalty for unprotected action, and by law workers may not be paid during industrial action.
=== Blood deserts === Since blood products acquisition, storage, transportation, and administration requires extensive infrastructure, there are several regions in which there is no blood, colloquially referred to as blood deserts. In these regions, blood transfusion is often not possible, and communities may have to rely on the commonly illegal practice of drawing blood directly from other community members. Blood deserts are a serious global health crisis that affects many people every year.
==== European Union ==== In June 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of the combination for the treatment of cystic fibrosis. It was approved for medical use in the European Union in August 2020.
Sources: en.wikipedia.org
=== Surface-induced dissociation === With surface-induced dissociation (SID), the fragmentation is a result of the collision of an ion with a surface under high vacuum. Today, SID is used to fragment a wide range of ions. Years ago, it was only common to use SID on lower mass, singly charged species because ionization methods and mass analyzer technologies weren't advanced enough to properly form, transmit, or characterize ions of high m/z. Over time, self-assembled monolayer surfaces (SAMs) composed of CF3(CF2)10CH2CH2S on gold have been the most prominently used collision surfaces for SID in a tandem spectrometer. SAMs have acted as the most desirable collision targets due to their characteristically large effective masses for the collision of incoming ions. Additionally, these surfaces are composed of rigid fluorocarbon chains, which don't significantly dampen the energy of the projectile ions. The fluorocarbon chains are also beneficial because of their ability to resist facile electron transfer from the metal surface to the incoming ions. SID's ability to produce subcomplexes that remain stable and provide valuable information on connectivity is unmatched by any other dissociation technique. Since the complexes produced from SID are stable and retain distribution of charge on the fragment, this produces a unique, spectra which the complex centers around a narrower m/z distribution. The SID products and the energy at which they form are reflective of the strengths and topology of the complex.
Paleolithic hunting and gathering people ate varying proportions of vegetables (including tubers and roots), fruit, seeds (including nuts and wild grass seeds) and insects, meat, fish, and shellfish. However, there is little direct evidence of the relative proportions of plant and animal foods. Although the term "paleolithic diet", without references to a specific timeframe or locale, is sometimes used with an implication that most humans shared a certain diet during the entire era, that is not entirely accurate. The Paleolithic was an extended period of time, during which multiple technological advances were made, many of which had impact on human dietary structure. For example, humans probably did not possess the control of fire until the Middle Paleolithic, or tools necessary to engage in extensive fishing. On the other hand, both these technologies are generally agreed to have been widely available to humans by the end of the Paleolithic (consequently, allowing humans in some regions of the planet to rely heavily on fishing and hunting). In addition, the Paleolithic involved a substantial geographical expansion of human populations. During the Lower Paleolithic, ancestors of modern humans are thought to have been constrained to Africa east of the Great Rift Valley. During the Middle and Upper Paleolithic, humans greatly expanded their area of settlement, reaching ecosystems as diverse as New Guinea and Alaska, and adapting their diets to whatever local resources were available.
=== Early student activism: 1966–1968 === Biko was initially interested in studying law at university, but many of those around him discouraged this, believing that law was too closely intertwined with political activism. Instead they convinced him to choose medicine, a subject thought to have better career prospects. He secured a scholarship, and in 1966 entered the University of Natal Medical School. There, he joined what his biographer Xolela Mangcu called "a peculiarly sophisticated and cosmopolitan group of students" from across South Africa; many of them later held prominent roles in the post-apartheid era. The late 1960s was the heyday of radical student politics across the world, as reflected in the protests of 1968, and Biko was eager to involve himself in this environment. Soon after he arrived at the university, he was elected to the Students' Representative Council (SRC). The university's SRC was affiliated with the National Union of South African Students (NUSAS). NUSAS had taken pains to cultivate a multi-racial membership but remained white-dominated because the majority of South Africa's students were from the country's white minority. As Clive Nettleton, a white NUSAS leader, put it: "the essence of the matter is that NUSAS was founded on white initiative, is financed by white money and reflects the opinions of the majority of its members who are white". NUSAS officially opposed apartheid, but it moderated its opposition in order to maintain the support of conservative white students.
=== Disadvantages === Reduced immunogenicity compared to attenuated vaccines Require adjuvants to improve immunogenicity Often require multiple doses ("booster" doses) to provide long-term immunity Can be difficult to isolate the specific antigen(s) which will invoke the necessary immune response It is not easy to supervise conjugation chemistry which leads to noncontinuous variation
Sources: en.wikipedia.org
Produced by Sandy Balfour, made by Double Exposure 4 October Homes on Wheels, about the one in twelve Americans, who live in a mobile home; Allan Wallis; David Thornburg (Galloping Bungalows), and the Tin Can Tourists in 1919; Randall Henderson; Glenn Curtiss Aerocar; Arthur Sherman in the 1930s; the Airstream from William Bowlus of Ryan Aircraft, originally made by Bowlus-Teller then by Wally; designer William Stout; Wilbur Bontrager of Jayco; Lazydays and the Family Motor Coach Association. Directed by George Haggerty, produced by Mike Wallington, made by Kai Productions 11 October Born That Way?, about the work of the homosexual British neuroscientist Simon LeVay, meeting a religious opponent of homosexuality, and a psychotherapist who thought that being homosexual was a mental illness; the Salk Institute for Biological Studies, and work on the INAH 3 in the hypothalamus; the work of Magnus Hirschfeld; endocrinologist Günter Dörner of the Humboldt University of Berlin; Louis P. Sheldon of the Traditional Values Coalition, did not approve of any promotion of homosexuality; until 1973 in the US, homosexuality was regarded as a deviant sexual predilection, and thought to be a mental illness; many US psychiatrists thought homosexuality to be a type of mental disorder, notably Charles W. Socarides; Richard Green (sexologist); Dulwich College; psychiatrist Richard Pillard; psychologist J.
identify metabolic disease signatures assess treatment class (pre- or post-treatment) identify compounds present in a patient sample that may alter drug response, or be caused by a therapy identify metabolite variables and interactions among these variables map identified variables to known metabolic and biochemical pathways
Each member of the population typically progresses from susceptible to infectious to recovered. This can be shown as a flow diagram in which the boxes represent the different compartments and the arrows the transition between compartments (see diagram).
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.